Epidemiological Study on Community Acquired Pneumonia

NCT ID: NCT02139163

Last Updated: 2020-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-10-31

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia. The aim of the study CAPNETZ is to improve diagnosis, treatment and patient care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Community Acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with pneumonia

Cohort Study

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cohort Study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥ 18
* infiltrate on chest X-ray

Exclusion Criteria

* hospital inpatient treatment within the last 28 days
* Immune suppressed patients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hannover Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tobias Welte, Prof. Dr.

Role: STUDY_CHAIR

Hannover Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CAPNETZ FOUNDATION Hannover Medical School (MHH)

Hanover, Lower Saxony, Germany

Site Status RECRUITING

Hannover Medical School

Hanover, Lower Saxony, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tobias Welte, Prof.

Role: CONTACT

+49-511-532-5927

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Abrahamczik

Role: primary

+49-(0)511-532-5927

Kroener

Role: backup

+49-(0)511-532-4447

Tobias Welte, Prof.

Role: primary

+49-511-532-5927

References

Explore related publications, articles, or registry entries linked to this study.

Zobel K, Martus P, Pletz MW, Ewig S, Prediger M, Welte T, Buhling F; CAPNETZ study group. Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med. 2012 Feb 20;12:6. doi: 10.1186/1471-2466-12-6.

Reference Type RESULT
PMID: 22348735 (View on PubMed)

Klapdor B, Ewig S, Schaberg T, Rohde G, Pletz MW, Schutte H, Welte T; CAPNETZ study group. Presentation, etiology and outcome of pneumonia in younger nursing home residents. J Infect. 2012 Jul;65(1):32-8. doi: 10.1016/j.jinf.2012.02.003. Epub 2012 Feb 10.

Reference Type RESULT
PMID: 22330772 (View on PubMed)

Lepper PM, Ott S, Nuesch E, von Eynatten M, Schumann C, Pletz MW, Mealing NM, Welte T, Bauer TT, Suttorp N, Juni P, Bals R, Rohde G; German Community Acquired Pneumonia Competence Network. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ. 2012 May 28;344:e3397. doi: 10.1136/bmj.e3397.

Reference Type RESULT
PMID: 22645184 (View on PubMed)

Kolditz M, Hoffken G, Martus P, Rohde G, Schutte H, Bals R, Suttorp N, Pletz MW; CAPNETZ study group. Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis. 2012 Apr 13;12:90. doi: 10.1186/1471-2334-12-90.

Reference Type RESULT
PMID: 22501026 (View on PubMed)

Klapdor B, Ewig S, Pletz MW, Rohde G, Schutte H, Schaberg T, Welte T; CAPNETZ Study Group. Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J. 2012 May;39(5):1156-61. doi: 10.1183/09031936.00110911. Epub 2011 Nov 16.

Reference Type RESULT
PMID: 22088967 (View on PubMed)

Ewig S, Klapdor B, Pletz MW, Rohde G, Schutte H, Schaberg T, Bauer TT, Welte T; CAPNETZ study group. Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax. 2012 Feb;67(2):132-8. doi: 10.1136/thoraxjnl-2011-200630. Epub 2011 Nov 5.

Reference Type RESULT
PMID: 22058186 (View on PubMed)

Glockner V, Pletz MW, Rohde G, Rupp J, Witzenrath M, Barten-Neiner G, Kolditz M; CAPNETZ Study Group. Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool. Eur J Clin Microbiol Infect Dis. 2022 Apr;41(4):621-630. doi: 10.1007/s10096-022-04416-5. Epub 2022 Feb 8.

Reference Type DERIVED
PMID: 35137301 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1147-8393

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.